arbiter
JournalsPricingAccount

Societal value and health economic benefits of GLP‐1 drugs in the United States

Frederik Cyrus Roeder & Emil Panzaru

Economic Affairs2025https://doi.org/10.1111/ecaf.70011article
ABDC C
Weight
0.37

What the paper says

Abstract This article provides an overview of the health economics of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in the United States based on a selection of the key literature, with some comparison references to cost‐effectiveness in the United Kingdom. It discusses the potential health‐care cost savings and societal benefits of products such as semaglutide (Ozempic/Wegovy), followed by current pricing trends and coverage, concluding with methodological and policy implications. To correctly consider the greater positive effects of GLP‐1 agonists, standard methods of assessment must go beyond list prices and balance cost‐containment, equity, and access while preserving competition and choice in the health‐care market.

1 citation

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1111/ecaf.70011

Or copy a formatted citation

@article{frederik2025,
  title        = {{Societal value and health economic benefits of GLP‐1 drugs in the United States}},
  author       = {Frederik Cyrus Roeder & Emil Panzaru},
  journal      = {Economic Affairs},
  year         = {2025},
  doi          = {https://doi.org/https://doi.org/10.1111/ecaf.70011},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Societal value and health economic benefits of GLP‐1 drugs in the United States

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.37

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.16 × 0.4 = 0.06
M · momentum0.53 × 0.15 = 0.08
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.